BioSpace News Archive

BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, is pleased to announce it has been accepted for a poster presentation at the 61st Annual American Society of Hematology Meeting, which takes place from 7-10 December 2019 in Orlando, Florida.

Previously presented retrospective analysis showed that adult multiple sclerosis relapse patients taking Acthar Gel had a higher relapse resolution rate than those taking other late-line treatments

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter financial results on Wednesday, November 13, 2019.

Kamada Ltd. announced that it will release financial results for the third quarter and nine months ended September 30, 2019, prior to the open of the U.S. financial markets on Wednesday, November 13, 2019.

GEMINI Phase 3 placebo-controlled trial of AXS-05 in MDD completed enrollment and on track for readout of topline results by year-end 2019

Generated cash flows from operating activities of $151 million in the first nine months of 2019, compared to $98 million during the same period in 2018

AVEO Oncology and Biodesix, Inc. announced the initiation of the CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO’s potent hepatocyte growth factor inhibitory antibody product candidate, in combination with high-dose cytarabine vs. high-dose cytarabine alone in patients with relapsed and refractory acute myeloid leukemia.

Bristol-Myers Squibb Company announced the extension of the expiration date of the offers to exchange notes issued by Celgene Corp for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company and cash and the related consent solicitations being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments to the indentures governing the Celgene Notes.

Kala Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle Drug Delivery Technology, reported financial results for the third quarter ended September 30, 2019.

BioXcel Therapeutics, Inc. announced it will host a conference call and webcast on Thursday, November 14, 2019 at 8:30 AM Eastern Time to discuss its third quarter 2019 operating and financial results.